Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.60 Average Price Target from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $51.40.

Several analysts have recently commented on DYN shares. Guggenheim lifted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday. Morgan Stanley upped their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Oppenheimer reiterated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the sale, the director now owns 234,127 shares of the company’s stock, valued at $8,533,929.15. This trade represents a 25.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Cox acquired 32,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. This trade represents a -133.33 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. RTW Investments LP raised its stake in Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after buying an additional 431,503 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. boosted its position in shares of Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after acquiring an additional 331,940 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 6.3 %

Shares of NASDAQ:DYN opened at $28.39 on Friday. Dyne Therapeutics has a 52-week low of $9.76 and a 52-week high of $47.45. The stock has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10. The business has a fifty day moving average of $32.48 and a two-hundred day moving average of $35.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts anticipate that Dyne Therapeutics will post -3.02 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.